Daewoong Pharma (069620) — Cash Flow Quality Index
Daewoong Pharma (069620) has a Cash Flow Quality Index of 1.34x as of September 2025. Operating cash flow of ₩57.53 Billion exceeds net income of ₩43.09 Billion, indicating high earnings quality where cash backs reported profits. Explore how much of Daewoong Pharma's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Daewoong Pharma Cash Flow Quality Index (2007–2024)
Historical Cash Flow Quality Index for Daewoong Pharma across 15 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 069620 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Daewoong Pharma (2007–2024)
Year-by-year earnings quality comparison for Daewoong Pharma. For live market cap and the full company financial profile, see Daewoong Pharma (069620) total market value.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 2.38x | ₩51.49 Billion | ₩21.61 Billion | ▲ +114.7% |
| 2023 | 1.11x | ₩132.57 Billion | ₩119.45 Billion | ▼ -28.5% |
| 2022 | 1.55x | ₩118.21 Billion | ₩76.14 Billion | ▲ +57.2% |
| 2021 | 0.99x | ₩39.99 Billion | ₩40.48 Billion | ▼ -96.9% |
| 2020 | 32.17x | ₩100.98 Billion | ₩3.14 Billion | ▲ +1129.1% |
| 2019 | 2.62x | ₩57.60 Billion | ₩22.01 Billion | ▼ -20.5% |
| 2017 | 3.29x | ₩103.94 Billion | ₩31.58 Billion | ▲ +477.2% |
| 2016 | 0.57x | ₩15.38 Billion | ₩26.97 Billion | ▼ -31.8% |
| 2015 | 0.84x | ₩35.89 Billion | ₩42.93 Billion | ▲ +1.6% |
| 2014 | 0.82x | ₩25.95 Billion | ₩31.54 Billion | ▼ -11.3% |
| 2013 | 0.93x | ₩54.16 Billion | ₩58.40 Billion | ▼ -29.8% |
| 2012 | 1.32x | ₩45.02 Billion | ₩34.08 Billion | ▼ -15.9% |
| 2011 | 1.57x | ₩78.82 Billion | ₩50.19 Billion | ▲ +65.1% |
| 2008 | 0.95x | ₩31.33 Billion | ₩32.93 Billion | ▲ +117.3% |
| 2007 | 0.44x | ₩25.81 Billion | ₩58.95 Billion | — |